Tuesday, October 22, 2019 3:10:38 PM
On positive news with the price where it is today, there will be a rush to get in with essentially no due diligence. Even if the stock moves to well over a dollar, people just hearing about results will see it as very cheap, perhaps the same will apply at $5 or even $10. Eventually investors will recognize that nearly a billion shares are outstanding, and while a market cap of a billion or two is justified, $10 billion isn't yet justified, and the price will correct. It would be nice to buy back 2 or 3 shares for every share you sold, and still have money in your pocket. If emotion truly takes hold of the stock for awhile, I certainly intend to sell some of my position, and plan to buy back more than I sell, but put a lot more than that back in my pocket.
Of course there always is a risk, if some company is truly looking to buy the company, if it did reach over a $10 billion market cap on emotion, it's not impossible that it could be bought out for $20 billion at that time. Short term the purchaser may have overpaid, but that organization knows what it will be worth in time, and knowing what the company wanted, decided to meet that demand, rather than wait, and perhaps have competition.
If both DCVax-L and Direct prove beneficial in multiple cancers, they could easily be worth $100 billion in market cap to whoever purchases the company. It won't happen instantly, but a decade from now earnings from these vaccines could easily justify a $100 billion market cap, perhaps substantially more than that.
Gary
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM